This website has been developed by Besins Healthcare (UK) Ltd.

This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) within the UK.

Please confirm that:

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.

Why Testogel®?


Prior to testosterone initiation, all patients must undergo a detailed examination in order to exclude a risk of pre-existing prostate cancer. Careful and regular monitoring of the prostate gland and breast must be performed in accordance with recommended methods (digital rectal examination (DRE) and estimation of serum prostate specific antigen (PSA)) in patients receiving testosterone therapy at least once yearly and twice yearly in elderly patients and at-risk patients (those with clinical or familial risk factors).

It’s important to check if the patient has any of the following contraindications:

  • Cases of known or suspected prostatic cancer or breast carcinoma
  • Hypersensitivity to testosterone or any of the excipients

When prescribing Testogel®, treatment should only be started in adults as testosterone replacement therapy for male hypogonadism, when testosterone deficiency has been confirmed by clinical features and two separate blood testosterone measurements. Due to interlaboratory variability, all measurements of testosterone should be carried out by the same laboratory.1,2 A number of clinical tools, in addition to clinical guidelines, are available to help you decide when to treat patients.

  • Testosterone levels should be monitored at baseline and at regular intervals during treatment
  • Clinicians should adjust the dosage individually to ensure maintenance of eugonadal testosterone levels
  • In patients receiving long-term androgen therapy, the following laboratory parameters should also be monitored regularly: haemoglobin, and haematocrit (to detect polycythaemia), liver function tests, and lipid profile


  1. Testogel® 16.2 mg/g gel – Summary of Product Characteristics (SmPC) – Accessed February 2022.
  2. Testogel® 40.5 mg, transdermal gel in sachet – Summary of Product Characteristics (SmPC) – Accessed February 2022.
  3. Hackett G, Kirby M, Edwards D, et al. British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice. J Sex Med. 2017;14(12):1504–1523.

TES/2022/046. February 2023.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: